A regenerative medicine service line can be a strong fit for the concierge model: differentiated, membership-aligned, and grounded in an area patients are actively curious about. The practices that succeed with it treat compliance as the design constraint rather than an afterthought. This playbook walks through how to scope, source, and structure a regenerative offering that is both attractive and defensible.
Start With Scope, Not Products
The most common mistake is to start from a product a vendor is promoting and work backward. A durable service line starts from scope: what the practice is licensed and equipped to offer, what its patients actually want, and where the clear regulatory boundaries fall. Products are chosen to fit that scope, not the other way around.
Design Principle
Define what you will and will not offer before you evaluate a single product. A clear scope makes sourcing, consent, and marketing decisions almost automatic, because every choice is measured against it.
Understand the Two Product Categories You Are Likely to Encounter
- Compounded peptides: prescribed by a licensed provider and prepared by a 503A or 503B pharmacy, with eligibility tied to current FDA guidance. Often used as adjuvants to therapy within an appropriate prescribing context.
- Exosome products: not FDA-approved to treat disease, supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research.
These two categories sit in very different regulatory places and should never be marketed as interchangeable or as a single approved treatment. Keeping them distinct in your materials is one of the simplest ways to reduce exposure.
Build the Sourcing Foundation
A regenerative program is only as strong as the documentation behind it. Before a product enters the practice, the sourcing partner should be able to answer a short list of questions clearly and in writing.
| Requirement | Compounded Peptide | Exosome Product |
|---|---|---|
| Regulatory basis | Prescription plus 503A/503B compounding | Topical aesthetic use and research; not for treatment |
| Documentation | COA, lot number, pharmacy license | COA, vesicle count, sterility panel |
| Handling | Reconstitution per pharmacy guidance | Cold-chain, characterization on receipt |
| Claims | Within the prescribing context | No disease-treatment claims permitted |
Structure Consent and Patient Communication
- Describe the compounded, prescription nature of any peptide and the topical aesthetic intended use of any exosome product in plain language.
- Avoid any statement, verbal or written, that promises to treat, cure, or prevent a disease with a non-approved product.
- Document the informational, investigational, or cosmetic nature of the offering in the consent materials themselves.
- Keep clinical decision-making with the licensed prescriber and record it in the chart.
Market the Service Without Overstating It
Marketing is where good programs most often slip. The safe posture is to describe the science and the experience, not to promise outcomes. Cosmetic offerings can speak to appearance and skin quality. Educational content can describe what peptides and exosomes are and how they are studied. What marketing cannot do is imply an approved treatment where none exists.
A regenerative service line is a documentation business as much as a clinical one. The practices that win treat both with equal care.
A Simple Launch Sequence
- Define scope and the boundaries you will not cross.
- Select sourcing partners who verify licensure and provide documentation on every lot.
- Draft consent and patient materials that describe categories accurately.
- Train staff so that verbal descriptions match the written materials.
- Review the program on a schedule as FDA guidance and product status change.
Compliance Note
Regulatory guidance evolves. A program that is compliant at launch needs periodic review to stay that way. Build that review into the operating rhythm of the service line from day one.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical, legal, or business advice. Exosome material referenced is supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and is not FDA-approved to diagnose, treat, cure, or prevent any disease. Compounded peptides require a valid prescription and appropriate pharmacy licensure. Practitioners are responsible for compliance with all applicable state and federal regulations.
References
- 1.U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers (Sections 503A and 503B). fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.
- 2.U.S. Food & Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes.
- 3.Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.